ERBB2 and non-small cell lung carcinoma: Over the years, understanding the molecular landscape of HER2 in NSCLC has evolved, leading to the development of targeted therapies such as ADCs like T-DXd and combinations with ICIs and TKIs, and the emergence of novel HER2-specific, better-tolerated, and more efficacious TKIs such as zongertinib.